Registration for Organisations.
Your question is the starting point for discussion
AIMDay is not an academic conference in the traditional sense. Instead, questions from companies and organisations are the very core of the AIMDay format. Your challenges, formulated as one or more questions, set the agenda for face-to-face discussions with academics.
Please must submit the questions you want to discuss with experts across the following thematic areas;
- Drug Development – Across the full translational pipeline from target identification, novel therapeutic approaches, pre-clinical evaluation and clinical trials.
- Development of multi-omics approaches to disease phenotyping, biomarker discovery and validation and disease progression monitoring to better inform future treatment/ disease management.
- Development of imaging and image analysis methods to examine other diseases with tools for the eye, e.g. OCT imaging and fundus photography.
- Development of data/ AI approaches to real world evidence data for chronic eye disease that could improve the patient treatment pathways.
We welcome up to three questions from each participating company or organisation. Due to limited spaces we may ask you to merge related questions into one session.
To ensure your AIMDay workshop (s) are successful, we ask that at least two company representatives who are familiar with the question or challenge are available to participate in the event.
NB: Companies will be involved in an hour-long round-table discussion of their question(s), so please be prepared to introduce the challenge in detail to a bespoke team of scientific and research experts during your workshop.
AIMDay is a free, event hosted in Belfast, UK. Refreshments and a light lunch will be provided for attendees.
Join us at AIMDay Chronic Eye Disease by submitting your question(s) and registering by the closing date of Monday 15th January 2024.
If you have any questions, please email AIMDay Chronic Eye Disease at businessalliance@qub.ac.uk
Registration for Companies is closed.
If you have questions, please contact us.